Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug Therapy

ABSTRACT: Objective: In rare instances, cytopenias manifest as a complication of thyrotoxicosis. Here, we report a case of Graves disease (GD) thyrotoxicosis presenting as pancytopenia that resolved with antithyroid therapy. Methods: A 35-year-old male presented with fever and chills following an o...

Full description

Bibliographic Details
Main Authors: Jonathan C. Li, MD, Deepika Nandiraju, MD, Serge Jabbour, MD, FACP, FACE, Alan A. Kubey, MD
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:AACE Clinical Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S237606052030033X
id doaj-73b68c63e5c64ee584f6107945fa5c9f
record_format Article
spelling doaj-73b68c63e5c64ee584f6107945fa5c9f2021-04-30T07:23:16ZengElsevierAACE Clinical Case Reports2376-06052019-11-0156e388e392Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug TherapyJonathan C. Li, MD0Deepika Nandiraju, MD1Serge Jabbour, MD, FACP, FACE2Alan A. Kubey, MD3Address correspondence to Dr. Jonathan C. Li, 1025 Walnut Street #100, Philadelphia, PA 19107.; From the Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania and Internal Medicine and Pediatrics Residency Program, Christiana Care Health System, Newark, DelawareDivision of Endocrinology, Thomas Jefferson University Hospital, Philadelphia, PennsylvaniaDivision of Endocrinology, Diabetes &amp; Metabolic Diseases, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PennsylvaniaDivision of Hospital Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, and; Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota.ABSTRACT: Objective: In rare instances, cytopenias manifest as a complication of thyrotoxicosis. Here, we report a case of Graves disease (GD) thyrotoxicosis presenting as pancytopenia that resolved with antithyroid therapy. Methods: A 35-year-old male presented with fever and chills following an outpatient colonoscopy. Initial blood work revealed pancytopenia. Workup included viral antigen titers, blood cultures, rheumatologic antibodies, inflammatory markers, immunocompetency, nutrient deficiency, metal toxicity, and malignancy. Bone marrow aspirate was analyzed by microscope, flow cytometry, fluorescence in situ hybridization, and genetic analysis. Computed tomography scan of the chest, abdomen, and pelvis was obtained. Thyroid labs included thyroid-stimulating hormone, total triiodothyronine, free thyroxine, thyroid-stimulating immunoglobulin, anti-thyroid peroxidase antibody, and radioiodine uptake scan. Results: All workup above was non-revelatory except as follows. Imaging revealed thymic hyperplasia and splenomegaly. Thyroid labs revealed thyroid-stimulating hormone <0.02 μIU/mL (reference range is 0.30 to 5.00 μIU/mL), free thyroxine of 4.7 ng/dL (reference range is 0.7 to 1.7 ng/dL), total triiodothyronine of 191 pg/mL (reference range is 90 to 180 pg/mL), thyroid-stimulating immunoglobulin of 522% (reference range is <140%). Bone marrow biopsy was consistent with a reactive process suggesting an infectious or autoimmune process. Radioiodine uptake scan confirmed GD. He was discharged on antithyroid medication. Two-month follow-up labs revealed improved cell counts; his absolute neutrophil count was 1.94 × 109 cells/L (reference range is 1.50 to 8.00 × 109 cells/L), hemoglobin was 12.9 g/dL (reference range is 14.0 to 17.0 g/dL), and platelets were 153 × 109 cells/L (reference range is 140 to 400 × 109 cells/L). Definitive treatment was obtained with 12 mCi of 131-iodine. Conclusion: Pancytopenia and lymphoid organ hyperplasia (splenomegaly, thymic hyperplasia, and lymphadenopathy) have been previously reported to be associated with thyrotoxicosis secondary to GD, rarely simultaneously, and manifest from both thyrotoxic and immunologic mechanisms. After excluding alternative life-threatening pathologies, in such presentations, GD should be considered and treated if confirmed.http://www.sciencedirect.com/science/article/pii/S237606052030033X
collection DOAJ
language English
format Article
sources DOAJ
author Jonathan C. Li, MD
Deepika Nandiraju, MD
Serge Jabbour, MD, FACP, FACE
Alan A. Kubey, MD
spellingShingle Jonathan C. Li, MD
Deepika Nandiraju, MD
Serge Jabbour, MD, FACP, FACE
Alan A. Kubey, MD
Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug Therapy
AACE Clinical Case Reports
author_facet Jonathan C. Li, MD
Deepika Nandiraju, MD
Serge Jabbour, MD, FACP, FACE
Alan A. Kubey, MD
author_sort Jonathan C. Li, MD
title Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug Therapy
title_short Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug Therapy
title_full Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug Therapy
title_fullStr Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug Therapy
title_full_unstemmed Pancytopenia and Lymphoid Organ Hyperplasia in a Patient with Graves Disease: Response to Antithyroid Drug Therapy
title_sort pancytopenia and lymphoid organ hyperplasia in a patient with graves disease: response to antithyroid drug therapy
publisher Elsevier
series AACE Clinical Case Reports
issn 2376-0605
publishDate 2019-11-01
description ABSTRACT: Objective: In rare instances, cytopenias manifest as a complication of thyrotoxicosis. Here, we report a case of Graves disease (GD) thyrotoxicosis presenting as pancytopenia that resolved with antithyroid therapy. Methods: A 35-year-old male presented with fever and chills following an outpatient colonoscopy. Initial blood work revealed pancytopenia. Workup included viral antigen titers, blood cultures, rheumatologic antibodies, inflammatory markers, immunocompetency, nutrient deficiency, metal toxicity, and malignancy. Bone marrow aspirate was analyzed by microscope, flow cytometry, fluorescence in situ hybridization, and genetic analysis. Computed tomography scan of the chest, abdomen, and pelvis was obtained. Thyroid labs included thyroid-stimulating hormone, total triiodothyronine, free thyroxine, thyroid-stimulating immunoglobulin, anti-thyroid peroxidase antibody, and radioiodine uptake scan. Results: All workup above was non-revelatory except as follows. Imaging revealed thymic hyperplasia and splenomegaly. Thyroid labs revealed thyroid-stimulating hormone <0.02 μIU/mL (reference range is 0.30 to 5.00 μIU/mL), free thyroxine of 4.7 ng/dL (reference range is 0.7 to 1.7 ng/dL), total triiodothyronine of 191 pg/mL (reference range is 90 to 180 pg/mL), thyroid-stimulating immunoglobulin of 522% (reference range is <140%). Bone marrow biopsy was consistent with a reactive process suggesting an infectious or autoimmune process. Radioiodine uptake scan confirmed GD. He was discharged on antithyroid medication. Two-month follow-up labs revealed improved cell counts; his absolute neutrophil count was 1.94 × 109 cells/L (reference range is 1.50 to 8.00 × 109 cells/L), hemoglobin was 12.9 g/dL (reference range is 14.0 to 17.0 g/dL), and platelets were 153 × 109 cells/L (reference range is 140 to 400 × 109 cells/L). Definitive treatment was obtained with 12 mCi of 131-iodine. Conclusion: Pancytopenia and lymphoid organ hyperplasia (splenomegaly, thymic hyperplasia, and lymphadenopathy) have been previously reported to be associated with thyrotoxicosis secondary to GD, rarely simultaneously, and manifest from both thyrotoxic and immunologic mechanisms. After excluding alternative life-threatening pathologies, in such presentations, GD should be considered and treated if confirmed.
url http://www.sciencedirect.com/science/article/pii/S237606052030033X
work_keys_str_mv AT jonathanclimd pancytopeniaandlymphoidorganhyperplasiainapatientwithgravesdiseaseresponsetoantithyroiddrugtherapy
AT deepikanandirajumd pancytopeniaandlymphoidorganhyperplasiainapatientwithgravesdiseaseresponsetoantithyroiddrugtherapy
AT sergejabbourmdfacpface pancytopeniaandlymphoidorganhyperplasiainapatientwithgravesdiseaseresponsetoantithyroiddrugtherapy
AT alanakubeymd pancytopeniaandlymphoidorganhyperplasiainapatientwithgravesdiseaseresponsetoantithyroiddrugtherapy
_version_ 1721498480380215296